The Ministry of Industry and Trade and Czechinvest will try to attract investors to it
Prague, 28th November 2012: By developing the Biomedical and Biotechnological National Park, Olomouc, the Haná capital, becomes a Czech centre of biomedicine, biotechnology and related fields. Its occupation and formation of conditions for the users will be specified by the Ministry of Industry and Trade (CR) (CzechInvest Agency), the Statutory Town of Olomouc, Palacký University in Olomouc, Olomouc University Hospital, Cluster MedChemBio and Technology Park a.s., which was confirmed by signing a memorandum of cooperation.
"Investment projects in the field of biomedicine and biotechnology are an added value which is one of the pillars of competitiveness of our country. The aim of the Ministry of Industry and Trade and the CzechInvest Agency is to place the largest possible numbers of quality foreign and domestic investors in the park who will help to further develop this promising field in the Czech Republic," says the Director of EU funds, Research and Development of the Ministry of Industry and Trade, Peter Očko, who is also the Acting Director of CzechInvest.
The National Park of Biomedicine and Biotechnology will be located within the site of the Technology Park Olomouc-Hnevotin situated in SW part of the town off the R46 and R35 junction. With the support of the Statutory Town of Olomouc, it will be built by Technology Park, a.s. in collaboration with the GEMO Group companies. The park will provide infrastructure for established companies as well as for spin-off and start-up companies from the university research environment. It will offer positions for postgraduate students and other specialists from the Olomouc region.
More than 23,000 students are studying at the Palacký University's eight faculties. The key research activities of the Olomouc University are focused on biomedicine, biotechnology and new materials. The conditions for the development of clinically oriented biomedical research and clinical studies of drugs, diagnostics, medical devices as well as technology of this field in the region are provided by the Olomouc University Hospital. The involvement of the Medicinal Chemistry and Chemical Biology (MedChemBio) Cluster provides the emerging project with a strong platform for the exchange of information, promotion of pharmacology, medicinal chemistry and chemical biology, the development of specific projects on the interface between science and industry in the development of new drugs and new diagnostic approaches, as well as communication between Czech and European entities.
Contact to the Ministry of Industry and Trade:
Veronika Forejtová, spokesperson, phone: +420 602 132 442, e-mail: firstname.lastname@example.org
Contact to CzechInvest:
Adéla Tomíčková – spokesperson, phone: +420 724 773 921, e-mail: email@example.com
CONTACT TO THE STATUTORY TOWN OF OLOMOUC:
Radka Štědrá, head of media communication department, spokesperson, tel.: +420 603 488 208, e-mail: firstname.lastname@example.org
CONTACT TO THE OLOMOUC UNIVERSITY HOSPITAL:
Egon Havrlant, spokeperson, phone: +420 606 607 687, e-mail: email@example.com
CONTACT TO PALACKÝ UNIVERSITY OLOMOUC
Vladimír Mišauer, marketing manager of BIOMEDREG – IMTM, Medical Faculty of UP in Olomouc, phone: +420 603 444 627, e-mail: firstname.lastname@example.org
CONTACT TO MEDCHEMBIO:
Arnošt Rybář, project manager, tel.: +420 733 690 653, e-mail: email@example.com
CONTACT TO TECHNOLOGY PARK, a.s.:
Šárka Havlíčková, phone: +420 602 288 575, e-mail: firstname.lastname@example.org